The 10th Diabetes and Cancer Research Consortium (DCRC) workshop
Diabetes and cancer are common chronic diseases. In Europe alone, there are 55,4 million individuals living with diabetes, mainly type 2 diabetes; while there are an estimated 3,5 million new cancer cases per year. The two diseases co-occur more often than may be expected from their separate prevalence. The strength of the association between diabetes and cancer is different for different cancer types and it is still not fully explained.
Several potential mechanisms have been proposed and considered, including shared causes (e.g. obesity), interaction between mechanisms of importance for both diseases (e.g. insulin resistance, hyperinsulinemia, low grade inflammation), reverse causation (i.e. cancer causing diabetes), effects fo diabetes treatments (e.g. insulin) and epidemiological biases that may appear in routine registers.
At the same time, the presence of diabetes often has an adverse effect on cancer treatment, making it important to consider both diseases together in clinical care.
08:00-08:30 Registration and coffee
08:40-09:00 EASD Diabetes and Cancer Study Group/Dioabetes and Cancer Research Consortium
Andrew Renehan, Manchester University, UK
09:00-09:30 Epidemiology of diabetes and cancer: Lessons learned
Bendix Carstensen, Steno Diabetes Center, DK
09:30-10:00 Diabetes, insulin and cancer: Mechanistic evidence
Michael Pollak, McGill University, Canada
10:00-10:30 Coffee break
Heterogeneity of type 2 diabetes
Chair: Paul Franks, Lund University
10:30:11:00 Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables
Emma Ahlqvist, Lund University Diabetes Centre, Sweden
11:00-11:30 Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechansims and subtypes: A soft clustering analysis
Miriam S. Udler, Broad Institute/MGH, US
11:30-11:45 PanDIA-1 study: Early diagnosis of pancreatic cancer among subjects with new-onset diabetes
Rolf Ehrnström, Immunovia, Lund; Sweden
11:45-12:00 The impact of type 2 diabetes on survival in patients with cancer independent of its effect on survival in individuals without cancer: a matched cohort analysis
Nasra Alam, Manchester University, UK
Diabetes, metabolic traits and cancer risk
Chair: Sarah Wild, University of Edinburgh
13:00-13:30 What has been learned from Mendelian randomization studies?
Mattias Johansson, IARC, France
13:30-14:00 Obesity and smoking-related cancers: The me-Can Study
Tanja Stocks, Lund University, Sweden
14:00-14:30 Obesity complications and breast cancer
Ann Rosendahl, Lund University, Sweden
14:30-15:00 Coffee break
15:00-16:00 Short presentations
Diabetes Status and Mammographic Density as a Predictor of Breast Cancer Risk
Gertraud Maskarinec, University of Hawaii, US
Body size and the risk and prognosis of prostate cancer: a pooled Swedish study
Sylvia Jochems, Lund University, Sweden
Diabetes and prostate cancer
Danielle Crawley, King´s College London, UK
Type 1 diabetes and risk of cancer
Wuqing Huang, Lund University, Sweden
End of program
Organisers and funders
The symposium is organised by the EASD Diabetes and Cancer Study Group (DCSG)/Diabetes and Cancer Research Consortium (DCRC), Andrew Renehan (Manchester University) and Isabel Drake (Lund Unviersity). The symposium is funded by Stiftelsen för bekämpande av cancer vid Malmö Allmänna Sjukhus (MAS Cancer) and the Strategic Research Area (SRA) EpiHealth.
The symposium is targeted at clinicians and researchers at all levels interested in the link between diabetes, related traits and cancer. Registration is mandatory.
Register no laterthan 4 September 2019 to Gunilla Hughes Wulcan (gunilla.hughes_wulcan at med.lu.se.)
For any questions regarding the symposium, please contact Isabel Drake (isabel.drake at med.lu.se).